PharmaMar Licensing Partner Lotus Receives the TFDA’s Accelerated Approval of Zepzelca (lurbinectedin) for Metastatic Small Cell Lung Cancer in Taiwan
Shots:
- Zepzelca has received accelerated marketing approval from the TFDA for adult patients with metastatic SCLC with disease progression on or after Pt-based CT
- The approval was based on the open-label, multi-center, single-arm monotx. clinical trial evaluating lurbinectedin in 105 adult patients incl. patients with Pt-sensitive & Pt-resistant disease
- PharmaMar & Lotus collaborated in Nov 2021 where PharmaMar retain production rights & sell the product to Lotus for its clinical & commercial use while Lotus lead the marketing approval in Taiwan, get the right to market the compound exclusively. Zepzelca is already commercialized in markets outside of Taiwan, incl. major markets i.e., the US, EU, Singapore & South Korea
Ref: Pharmamar | Image: Pharmamar
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
